EP4319730A4 - PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING EPILEPTIC DISORDERS - Google Patents

PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING EPILEPTIC DISORDERS

Info

Publication number
EP4319730A4
EP4319730A4 EP22784263.0A EP22784263A EP4319730A4 EP 4319730 A4 EP4319730 A4 EP 4319730A4 EP 22784263 A EP22784263 A EP 22784263A EP 4319730 A4 EP4319730 A4 EP 4319730A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
seizure disorders
treating seizure
treating
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22784263.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4319730A1 (en
Inventor
Fotios M. Plakogiannis
Tamanna LATHER
Nisarg MODI
Marina BOROVINSKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/225,654 external-priority patent/US12016829B2/en
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of EP4319730A1 publication Critical patent/EP4319730A1/en
Publication of EP4319730A4 publication Critical patent/EP4319730A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22784263.0A 2021-04-08 2022-04-07 PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING EPILEPTIC DISORDERS Withdrawn EP4319730A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/225,654 US12016829B2 (en) 2019-10-11 2021-04-08 Pharmaceutical composition and method for treating seizure disorders
PCT/IB2022/053271 WO2022215030A1 (en) 2021-04-08 2022-04-07 Pharmaceutical composition and method for treating seizure disorders

Publications (2)

Publication Number Publication Date
EP4319730A1 EP4319730A1 (en) 2024-02-14
EP4319730A4 true EP4319730A4 (en) 2025-03-12

Family

ID=83546168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22784263.0A Withdrawn EP4319730A4 (en) 2021-04-08 2022-04-07 PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING EPILEPTIC DISORDERS

Country Status (7)

Country Link
EP (1) EP4319730A4 (enExample)
JP (1) JP2024514843A (enExample)
CN (1) CN117479930A (enExample)
AU (1) AU2022255944A1 (enExample)
CA (1) CA3213953A1 (enExample)
MX (1) MX2023011821A (enExample)
WO (1) WO2022215030A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
US20190231711A1 (en) * 2018-01-31 2019-08-01 Life Tech Global, Llc Dihydromyricetin Compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
JOP20200045A1 (ar) * 2017-09-19 2020-02-27 Zynerba Pharmaceuticals Inc كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
US12186280B2 (en) * 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
AU2021392090A1 (en) * 2020-12-03 2023-07-06 Harmony Biosciences Management, Inc. Cannabidiol for the treatment of refractory seizures

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
US20190231711A1 (en) * 2018-01-31 2019-08-01 Life Tech Global, Llc Dihydromyricetin Compositions

Also Published As

Publication number Publication date
EP4319730A1 (en) 2024-02-14
AU2022255944A1 (en) 2023-10-12
CN117479930A (zh) 2024-01-30
CA3213953A1 (en) 2022-10-13
MX2023011821A (es) 2023-10-13
WO2022215030A1 (en) 2022-10-13
JP2024514843A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
EP4324463A4 (en) Method and pharmaceutical composition for treating myopia
EP4352079A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROFIBROMATIC DISORDERS
EP3854804A4 (en) Method and composition for preventing and treating atherosclerosis and related diseases
EP4341382A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES
AU2024357318A1 (en) Methods and compositions for treating drug overdose
EP4175978A4 (en) COMPOSITIONS AND METHODS FOR TREATING CRP-MEDIATED DISEASES
CA3261972A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP4294793A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAUOPATHIES
AU2021407382A9 (en) Compositions and methods for anxiety disorder treatment
EP3965732A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA AND PROCESS FOR THEIR PREPARATION
EP4076668A4 (en) Composition and method for treating dermatological disorders using retinamides
CA3307442A1 (en) Methods and compositions for treating drug overdose
CA3297601A1 (en) Methods and compositions for treating ctnnb1-associated disorders
HK40131011A (en) Methods and compositions for treating hsd-1-mediated disorders
CA3278656A1 (en) Methods and compositions for treating hsd-1-mediated disorders
AU2022903123A0 (en) Compositions and methods for treating disorders
HK40110376A (en) Compositions and methods for treating neurofibromatic disorders
CA3299570A1 (en) Method and composition for treating diseases
CA3305935A1 (en) Compositions and methods for treating pain disorders
HK40085772A (en) Composition and method for treating chronic pain
CA3308877A1 (en) Compositions and methods for treating gastrointestinal-related diseases and disorders
AU2020901947A0 (en) Composition and method for treating chronic pain
CA3294308A1 (en) Formulations and methods for treating neuropsychiatric disorders
HK40089639A (en) Compositions and methods for treating neuropsychiatric disorders
AU2021903256A0 (en) Compositions and methods for treating neurological disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240227

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20250205BHEP

Ipc: A61K 45/06 20060101ALI20250205BHEP

Ipc: A61K 31/00 20060101ALI20250205BHEP

Ipc: C07C 39/23 20060101ALI20250205BHEP

Ipc: A61P 25/08 20060101ALI20250205BHEP

Ipc: A61K 9/70 20060101ALI20250205BHEP

Ipc: A61K 9/00 20060101ALI20250205BHEP

Ipc: A61K 31/05 20060101AFI20250205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250829